News
Nanexa, Novo Enter €1.165 Billion Drug Delivery Collaboration
Novo receives a global licence to use Nanexa’s proprietary ALD-based drug delivery platform for peptide drugs targeting obesity, type 2 diabetes and other cardiometabolic diseases.


